All In Biotech

NDA 212097 · Xeris

Gvoke Kit

Glucagon · Subcutaneous, Intravenous · Antihypoglycemic Agent; Gastrointestinal Motility Inhibitor

Last checked: Nov 20, 2026Latest source record: Mar 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Sep 10, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,154

249 Phase 3, 171 recruiting

FAERS reports

16

7 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2026.

GVOKE is an antihypoglycemic agent indicated for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients aged two years and older with diabetes ( 1.1 ) GVOKE VialDx is a gastrointestinal motility inhibitor indicated for intravenous use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients ( 1.2 ) 1.1 Severe Hypoglycemia in Adult and Pediatric Patients Aged 2 Years and Older with Diabetes GVOKE is indicated for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients aged two and older with diabetes. 1.2 Diagnostic Aid in Adults GVOKE VialDx is indicated for intravenous use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • GVOKE KIT · GLUCAGON 1MG/0.2ML (1MG/0.2ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • GVOKE HYPOPEN · GLUCAGON 0.5MG/0.1ML (0.5MG/0.1ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • GVOKE PFS · GLUCAGON 0.5MG/0.1ML (0.5MG/0.1ML) · SOLUTION, SUBCUTANEOUS · Discontinued
  • GVOKE VIALDX · GLUCAGON 1MG/0.2ML (1MG/0.2ML) · SOLUTION, INTRAVENOUS · Discontinued
  • GVOKE HYPOPEN · GLUCAGON 1MG/0.2ML (1MG/0.2ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • GVOKE PFS · GLUCAGON 1MG/0.2ML (1MG/0.2ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Glucagon" as an intervention, any sponsor and status, largest first.

All 1,154 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose decreased3
  • constipation2
  • death2
  • dizziness2
  • screaming2
  • abdominal pain1
  • abdominal pain upper1
  • aphasia1
  • arthralgia1
  • atrial fibrillation1
  • blood creatinine increased1
  • blood pressure systolic decreased1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20141
20203
20211
20221
20232
20241
20253
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,332 on PubMed

Sponsor: Xeris · Also marketed as Gvoke Hypopen, Gvoke Pfs, Gvoke Vialdx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.